China NMPA Drug Inspection - Jiangxi Xinjian Pharmaceutical Co., Ltd. - safflower

The National Medical Products Administration (NMPA) issued Announcement No. 58 on December 25, 2024, identifying 27 batches of drugs from 12 pharmaceutical companies that failed to meet national quality standards. Testing conducted by various regional institutes revealed multiple safety and quality concerns. Beijing Shuanglu Pharmaceutical Co., Ltd. was cited for 14 batches of cyclosporine capsules with appearance and weight variation issues. Guangxi Ritian Pharmaceutical Group failed microbial limit tests, while Heilongjiang Shenge Pharmaceutical was flagged for incorrect ingredient concentrations. Other companies, including Hebei Honghan Pharmaceutical and several traditional medicine suppliers like Anhui Wansheng and Jiangxi Qirentang, produced herbal products that failed physical property inspections. Under the Drug Administration Law of the People's Republic of China, the NMPA has mandated immediate risk control measures. Affected companies must suspend sales and use of the non-compliant batches and initiate product recalls. Furthermore, the NMPA directed provincial authorities to investigate potential illegal activities, determine the causes of failure, and implement corrective actions. All investigation results will be publicly disclosed to ensure transparency and public health safety.